Baird Medical Stock Price, News & Analysis

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, hosted an advanced training session and academic exchange in New Orleans. The program featured collaboration between Dr. Emad Kandil, Professor at Tulane University School of Medicine, and Dr. Gregory Randolph, Professor at Harvard Medical School and Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology.

During the May 9, 2025 event, the experts engaged in academic discussions on thyroid-focused topics, conducted clinical observations, and performed hands-on procedures. The initiative is part of Baird Medical's strategy to promote excellence in thyroid care through partnerships with medical leaders and support global adoption of minimally invasive therapies.

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, announces its participation in the 45th Annual Meeting of the American Association of Endocrine Surgeons (AAES). The event will take place from May 17-19, 2025, at the Baird Center in Milwaukee, Wisconsin.

The AAES Annual Meeting, North America's premier gathering of endocrine surgeons, focuses on advancing endocrine surgery through research presentations, expert panels, and discussions on thyroid diseases, parathyroid, adrenal glands, and endocrine pancreas. Baird Medical's participation underscores the importance of its MWA technology in minimally invasive treatments for endocrine conditions, particularly thyroid nodules.

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, has announced its participation in the 2025 Combined Otolaryngology Spring Meetings (COSM) scheduled for May 14-18, 2025, in New Orleans, Louisiana.

COSM is a prestigious international gathering for the otolaryngology-head and neck surgery community, bringing together multiple leading societies. The conference provides Baird Medical with a strategic platform to showcase its MWA technology portfolio and engage with key opinion leaders, clinicians, researchers, and potential strategic partners in the otolaryngology field.

Baird Medical (NASDAQ: BDMD), a leader in Microwave Ablation (MWA) technology, hosted an advanced MWA training session in New Orleans. The program was led by Dr. Emad Kandil, Professor at Tulane University School of Medicine, training Dr. Shahzad Ahmad, an endocrinologist and thyroid specialist from Salt Lake City.

During the session, Dr. Ahmad, who serves as Treasurer of the North American Society of Interventional Endocrinology (NASOIE), observed four live MWA procedures and participated in hands-on training. The program concluded with discussions on implementing MWA across clinical settings and the awarding of a Certificate of Completion.

Baird Medical Investment Holdings (NASDAQ: BDMD) hosted a delegation of Malaysian thyroid specialists for advanced microwave ablation (MWA) training in China. The intensive clinical training and academic exchange took place at the Eighth Affiliated Hospital of Sun Yat-sen University and Shenzhen People's Hospital.

The comprehensive program included expert-led demonstrations, hands-on workshops, and live observation of MWA procedures. Participants engaged in discussions about procedural techniques, patient selection criteria, and post-treatment outcomes. According to Chairwoman Haimei Wu, these international exchanges play a important role in accelerating the global adoption of innovative thyroid treatment techniques.

Baird Medical (NASDAQ: BDMD) recently hosted Dr. Gary G. Tse, an interventional radiologist from UCLA Health, for a clinical visit in Guangzhou, China. The visit showcased the company's advanced microwave ablation (MWA) technology for minimally invasive thyroid treatments.

During the visit at Sun Yat-sen University Cancer Center, Dr. Tse observed multiple thyroid nodule ablation procedures using Baird Medical's MWA system. The visit also included academic discussions with Dr. Michael Mingzhao Xing from Johns Hopkins University School of Medicine, focusing on advancements in thyroid nodule management.

Baird Medical (NASDAQ: BDMD) has achieved a significant expansion milestone as the FDA issued a Certificate to Foreign Government for Egyptian regulatory authorities, validating their compliance with U.S. medical device standards. The company has submitted regulatory registration applications in multiple Asian and Middle Eastern markets including Egypt, Hong Kong, Thailand, Malaysia, Kazakhstan, Sri Lanka, and India.

Following their March 2025 regulatory approval in Indonesia, Baird Medical is establishing partnerships with healthcare institutions across these regions to develop distribution networks and training programs for their microwave ablation (MWA) technology. This minimally invasive procedure, used in treating thyroid nodules and tumors, employs targeted microwave energy for precise ablation with high efficiency and effective hemostasis, while minimizing damage to healthy tissues.

Baird Medical (NASDAQ: BDMD) hosted Dr. Quan-Yang Duh, Chief of Endocrine Surgery at UCSF, for a clinical observation visit in Guangzhou and Shenzhen, China. The visit showcased Baird Medical's microwave ablation (MWA) technology in action.

At Sun Yat-sen University Cancer Center, Dr. Duh observed several thyroid ablation cases, including a notable procedure performed by Dr. Feng Han treating bilateral thyroid nodules with a 4 cm lesion. The procedure demonstrated the minimally invasive nature of the MWA system, with the patient remaining awake throughout.

In Shenzhen, Dr. Duh observed additional MWA procedures and delivered a presentation on surgical management of thyroid diseases. The visit included academic discussions with specialists about integrating microwave ablation with surgical approaches.

Baird Medical Investment Holdings (NASDAQ: BDMD) has announced the successful implementation of its microwave ablation (MWA) technology in two endocrine procedures. The procedures were performed by Dr. Saka Kazeem, an endocrinologist with over 30 years of experience.

Dr. Kazeem, using the MWA system for the first time, commended its efficiency and seamless integration into clinical practice, noting its intuitive nature and optimization of procedure time without compromising patient outcomes. Chairwoman Haimei Wu emphasized the technology's value in improving clinical workflows and patient care.

The company has expressed its commitment to expanding its presence and collaborating with medical professionals to advance MWA technology applications.